ACE
Angiotensin-converting enzyme
As of the edition of 20 October 2026, ACE (angiotensin-converting enzyme, UniProt P12821) has 17 drugs tested at it and 18 companies on the list, 0 on route A and 10 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P12821
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 97
- Disease areas
- Heart and blood vessels; Urinary and reproductive; Nutrition and metabolism; Pregnancy and women's health; Hormones; Inherited and neonatal; Cancer; Immune system
- Registered trials of its drugs
- 372
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 16 |
| Went quiet | 1 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ramipril | Marketed | Phase 4 | none listed |
| Lisinopril anhydrous | Marketed | Phase 4 | none listed |
| Enalapril | Marketed | Phase 4 | none listed |
| Benazepril | Marketed | Phase 4 | none listed |
| Perindopril | Marketed | Phase 4 | none listed |
| Captopril | Marketed | Phase 4 | none listed |
| Quinapril | Marketed | Phase 4 | none listed |
| Trandolapril | Marketed | Phase 4 | none listed |
| Fosinopril | Marketed | Phase 4 | none listed |
| Enalaprilat anhydrous | Marketed | Phase 4 | none listed |
| Moexipril | Marketed | Phase 2 | none listed |
| Imidapril | Marketed | Phase 3 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 10 |
| Undetermined | 8 |
| Total on the list | 18 |
| Company | Route |
|---|---|
| Sanofi | Route B |
| AbbVie | Route B |
| Bristol Myers Squibb | Route B |
The other 15 companies at ACE
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at ACE, ranked, with the facts behind eachRequest access. Nothing is shown until you do.